Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308138727> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4308138727 endingPage "A658" @default.
- W4308138727 startingPage "A658" @default.
- W4308138727 abstract "Abstract Introduction Sodium-glucose cotransporter (SGLT) 2 inhibition is a well-known target for type 2 diabetes treatment, chronic heart failure and chronic kidney disease. SGLT2 is encoded by SLC5A2 (Solute Carrier Family 5 Member 2) gene, which is highly expressed in the kidney cortex(x36.9). Notably, SLC5A2is also overexpressed in the testes (x8.1), where glucose uptake could be crucial for androgen production and spermatogenesis. We hypothesized that the SGLT2 inhibitors use could interfere with testosterone production in healthy men. Method This is a post-hoc analysis of a double-blind, randomized, placebo-controlled study, in 27 healthy men who received empagliflozin 10mg once a day during 4 weeks. All weight categories were included: 15 normal weight, 15 overweight, 15 obese. In each group, 5 were randomized to the placebo and 10 to the empagliflozin. Serum samples were analyzed using an ultra-high-performance LC (UHPLC)–MS/MS method for quantification of total testosterone (TT) and dihydrotestosterone (DHT). TT and sex hormone-binding globulin were used to calculate free testosterone (FT). Results No significant changes were observed in total serum TT (Δ 2.1 nmol/L; p>0.1), DHT (Δ 0. 03 nmol/L; p>0.1) and FT (Δ 0.35 nmol/L; p>0.1) after one month of empagliflozin. Conclusion The use of a highly selective SGLT2 inhibitor, empagliflozin, in men without diabetes did not change serum androgen levels, regardless of body mass index category. Studies on seminiferous tubule function in healthy men are ongoing to further clarify the role of SGLT2 in spermatogenesis. Presentation: No date and time listed" @default.
- W4308138727 created "2022-11-08" @default.
- W4308138727 creator A5029020835 @default.
- W4308138727 creator A5050236395 @default.
- W4308138727 creator A5063789387 @default.
- W4308138727 creator A5066941637 @default.
- W4308138727 creator A5078556872 @default.
- W4308138727 creator A5087946690 @default.
- W4308138727 date "2022-11-01" @default.
- W4308138727 modified "2023-09-26" @default.
- W4308138727 title "ODP404 Effects of Empagliflozin on Serum Androgens Levels in Men Without Diabetes" @default.
- W4308138727 doi "https://doi.org/10.1210/jendso/bvac150.1360" @default.
- W4308138727 hasPublicationYear "2022" @default.
- W4308138727 type Work @default.
- W4308138727 citedByCount "0" @default.
- W4308138727 crossrefType "journal-article" @default.
- W4308138727 hasAuthorship W4308138727A5029020835 @default.
- W4308138727 hasAuthorship W4308138727A5050236395 @default.
- W4308138727 hasAuthorship W4308138727A5063789387 @default.
- W4308138727 hasAuthorship W4308138727A5066941637 @default.
- W4308138727 hasAuthorship W4308138727A5078556872 @default.
- W4308138727 hasAuthorship W4308138727A5087946690 @default.
- W4308138727 hasBestOaLocation W43081387271 @default.
- W4308138727 hasConcept C126322002 @default.
- W4308138727 hasConcept C134018914 @default.
- W4308138727 hasConcept C142724271 @default.
- W4308138727 hasConcept C204787440 @default.
- W4308138727 hasConcept C27081682 @default.
- W4308138727 hasConcept C2775887513 @default.
- W4308138727 hasConcept C2777180221 @default.
- W4308138727 hasConcept C2777911890 @default.
- W4308138727 hasConcept C2779279991 @default.
- W4308138727 hasConcept C2779881493 @default.
- W4308138727 hasConcept C2780221984 @default.
- W4308138727 hasConcept C2780586474 @default.
- W4308138727 hasConcept C30092816 @default.
- W4308138727 hasConcept C555293320 @default.
- W4308138727 hasConcept C71315377 @default.
- W4308138727 hasConcept C71924100 @default.
- W4308138727 hasConceptScore W4308138727C126322002 @default.
- W4308138727 hasConceptScore W4308138727C134018914 @default.
- W4308138727 hasConceptScore W4308138727C142724271 @default.
- W4308138727 hasConceptScore W4308138727C204787440 @default.
- W4308138727 hasConceptScore W4308138727C27081682 @default.
- W4308138727 hasConceptScore W4308138727C2775887513 @default.
- W4308138727 hasConceptScore W4308138727C2777180221 @default.
- W4308138727 hasConceptScore W4308138727C2777911890 @default.
- W4308138727 hasConceptScore W4308138727C2779279991 @default.
- W4308138727 hasConceptScore W4308138727C2779881493 @default.
- W4308138727 hasConceptScore W4308138727C2780221984 @default.
- W4308138727 hasConceptScore W4308138727C2780586474 @default.
- W4308138727 hasConceptScore W4308138727C30092816 @default.
- W4308138727 hasConceptScore W4308138727C555293320 @default.
- W4308138727 hasConceptScore W4308138727C71315377 @default.
- W4308138727 hasConceptScore W4308138727C71924100 @default.
- W4308138727 hasIssue "Supplement_1" @default.
- W4308138727 hasLocation W43081387271 @default.
- W4308138727 hasLocation W43081387272 @default.
- W4308138727 hasOpenAccess W4308138727 @default.
- W4308138727 hasPrimaryLocation W43081387271 @default.
- W4308138727 hasRelatedWork W1981433740 @default.
- W4308138727 hasRelatedWork W2006690885 @default.
- W4308138727 hasRelatedWork W2016149193 @default.
- W4308138727 hasRelatedWork W2024718203 @default.
- W4308138727 hasRelatedWork W2027210979 @default.
- W4308138727 hasRelatedWork W2030295611 @default.
- W4308138727 hasRelatedWork W2059176014 @default.
- W4308138727 hasRelatedWork W2071498212 @default.
- W4308138727 hasRelatedWork W2148405763 @default.
- W4308138727 hasRelatedWork W2164737224 @default.
- W4308138727 hasVolume "6" @default.
- W4308138727 isParatext "false" @default.
- W4308138727 isRetracted "false" @default.
- W4308138727 workType "article" @default.